Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials - Concepedia

Concepedia

Publication | Open Access

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials

DOI Full Paper Access

75

Citations

25

References

2017

Year

Frédéric Vanhoutte, Minodora Mazur, O.I. Voloshyn, Mykola Stanislavchuk, Annegret Van der Aa, Florence Namour, René Galien, Luc Meuleners, Gerben van ‘t Klooster

Arthritis & Rheumatology

Abstract

Selective inhibition of JAK-1 with filgotinib shows initial efficacy in RA with an encouraging safety profile in these exploratory studies.

References

	Year	Citations
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis Frank C. Arnett, Steven M. Edworthy, D. Blöch, Arthritis & Rheumatism	1988	19.8K
Revised Criteria for the Classification of Rheumatoid Arthritis Frank C. Arnett Orthopaedic Nursing Rheumatoid DisorderRheumatologyAutoimmune DiseaseRheumatic DiseasesClassification Criteria	1990	7.7K
Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis M.L.L. Prevoo, Martin A. van't Hof, H. H. Kuper, Arthritis & Rheumatism	1995	6.1K
Measurement of patient outcome in arthritis James F. Fries, Patricia W. Spitz, R. Guy Kraines, Arthritis & Rheumatism Rheumatoid DisorderRheumatologyRheumatic DiseasesQuestionnaire TechniquePatient Outcome	1980	4.3K
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis David T. Felson, Jennifer J. Anderson, Maarten Boers, Arthritis & Rheumatism	1995	2.8K
The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials David T. Felson, Jennifer J. Anderson, Maarten Boers, Arthritis & Rheumatism	1993	1.6K
Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis Hans Neubauer, Ana Cumano, Mathias Müller, Cell Developmental BiologyCell DivisionReceptor Tyrosine KinaseCell CycleJak2 Deficiency Defines	1998	907
Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses Scott J. Rodig, Marco Antonio Meraz‐Ríos, J. Michael White, Cell InflammationCytokineSignal TransductionAutoimmune DiseaseReceptor Tyrosine Kinase	1998	842
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld, Arthritis & Rheumatism	2009	541
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Arthritis & Rheumatism	2011	343

Page 1